At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study of Nivolumab (BMS-936558) in Combination With Ipilimumab (BMS-734016) in Chinese Participants With Previously Treated Metastatic or Recurrent Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Ipilimumab for Solid Tumor. Completed, enrolled 37 participants across 12 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartAug 2017
Primary CompletionJan 2024
TodayJul 2026
First PostedJun 22, 2017
Enrollment StartAug 2, 2017
Primary CompletionJan 5, 2024
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 9.0 years ago
Interventions
Nivolumabdrug
Specified dose on specified days
Ipilimumabdrug
Specified dose on specified days